Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jul 3:17:1963-1978.
doi: 10.2147/DDDT.S416091. eCollection 2023.

Untapping the Potential of Astragaloside IV in the Battle Against Respiratory Diseases

Junlan Tan  1   2 , Jian Yi  2   3 , Xianya Cao  1   2 , Feiying Wang  2   4 , Silin Xie  2   4 , Aiguo Dai  2   4   5
Affiliations
Review

Untapping the Potential of Astragaloside IV in the Battle Against Respiratory Diseases

Junlan Tan et al. Drug Des Devel Ther. .

Abstract

Respiratory diseases are an emerging public health concern, that pose a risk to the global community. There, it is essential to establish effective treatments to reduce the global burden of respiratory diseases. Astragaloside IV (AS-IV) is a natural saponin isolated from Radix astragali (Huangqi in Chinese) used for thousands of years in Chinese medicine. This compound has become increasingly popular due to its potential anti-inflammatory, antioxidant, and anticancer properties. In the last decade, accumulated evidence has indicated the AS-IV protective effect against respiratory diseases. This article presents a current understanding of AS-IV roles and mechanisms in combatting respiratory diseases. The ability of the agent to suppress oxidative stress, cell proliferation, and epithelial-mesenchymal transition (EMT), to attenuate inflammatory responses, and modulate programmed cell death (PCD) will be discussed. This review highlights the current challenges in respiratory diseases and recommendations to improve disease management.

Keywords: Radix astragali; astragaloside IV; inflammatory responses; oxidative stress; respiratory diseases.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Brief introduction and profile of AS-IV. AS-IV is a natural saponin isolated extracted from Radix astragali (Huangqi in Chinese) and possesses a wide range of pharmacological activities including respiratory diseases treatment.
Figure 2
Figure 2
The targets and pathways of AS-IV in treating PH. (A). AS-IV inhibits PASMCs proliferation by suppressing Notch3 and RhoA pathway. (B). AS-IV ameliorated apoptosis resistance in PASMCs by downregulating Bcl-2, phospho-ERK, and HIF-1α expressions. (C). AS-IV attenuates inflammatory response mediated by NLRP-3/calpain-1. Created with BioRender.com.
Figure 3
Figure 3
The targets and pathways of AS-IV in treating PF. (A). AS-IV inhibits the TGF-β1/Smads signaling pathway by suppressing MTA1 and NLRP3 expression, thereby inhibiting EMT; AS-IV also inhibits EMT by suppressing the TGF-β1/PI3K/AKT/Foxo3α signaling pathway. (B). AS-IV ameliorates oxidative stress via activation of Nrf2. (C). AS-IV alleviates inflammation by blocking NF-κB activation. (D). AS-IV blocks the differentiation of lung fibroblasts to myofibroblasts by inhibiting the TGF-β1/Smads signaling pathway. Created with BioRender.com.
Figure 4
Figure 4
The general map of AS-IV in treating various respiratory diseases. Created with BioRender.com.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Li X, Cao X, Guo M, et al. Trends and risk factors of mortality and disability adjusted life years for chronic respiratory diseases from 1990 to 2017: systematic analysis for the Global Burden of Disease Study 2017. BMJ. 2020;368:m234. doi:10.1136/bmj.m234 - DOI - PMC - PubMed
    1. GBD Chronic Respiratory Disease Collaborators. Prevalence and attributable health burden of chronic respiratory diseases, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Respir Med. 2020;8(6):585–596. doi:10.1016/S2213-2600(20)30105-3 - DOI - PMC - PubMed
    1. Liu Y, Tong C, Tang Y, et al. Tanshinone IIA alleviates blast-induced inflammation, oxidative stress and apoptosis in mice partly by inhibiting the PI3K/Akt/FoxO1 signaling pathway. Free Radic Biol Med. 2020;152:52–60. doi:10.1016/j.freeradbiomed.2020.02.032 - DOI - PubMed
    1. Huang B, Hao M, Li C, et al. Acetyltanshinone IIA reduces the synthesis of cell cycle-related proteins by degrading p70S6K and subsequently inhibits drug-resistant lung cancer cell growth. Pharmacol Res. 2022;179:106209. doi:10.1016/j.phrs.2022.106209 - DOI - PubMed
    1. Li H, Wu M, Guo C, et al. Tanshinone IIA regulates Keap1/Nrf2 signal pathway by activating sestrin2 to restrain pulmonary fibrosis. Am J Chin Med. 2022;50(8):2125–2151. doi:10.1142/S0192415X22500914 - DOI - PubMed